Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
BIO-key International's Chairman and CEO will present at the RedChip Future Tech Investor Conference, highlighting the company's significant revenue growth and anticipated profitability in the first half of 2026. The company, a leader in biometric authentication and identity access management, expects 1H 2026 revenues to increase by 50% compared to…
Ming Shing Group Holdings Limited reported the resignation of CEO Han Yan and independent director Dongjie Lao for personal reasons, with no disagreements involved. Zhijun Pan has been appointed as interim CEO, and the company is searching for a permanent replacement. Additionally, Tianhang Zhao has been re-designated as chairman of the compensatio…
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, completed the acquisition of a 54% interest in CliniQuantum Ltd., an Israeli company specializing in quantum simulation for clinical trial data analysis. The acquisition includes issuance of NeuroThera shares to CliniQuantum shareholders and potential earn-out payments contingent…
Plus Therapeutics announced that CNSide Diagnostics, its wholly owned subsidiary, has achieved College of American Pathologists (CAP) accreditation for its Houston-based clinical laboratory. This accreditation validates the laboratory's high standards and quality controls, strengthening its position to expand the commercial use of the CNSide® CSF A…
Rezolute, Inc., a late-stage biotech company focused on treatments for refractory hypoglycemia due to hyperinsulinism, announced four presentations at the 2026 Endocrine Society Annual Meeting. These include data from the Phase 3 sunRIZE study of their drug ersodetug, which previously failed to meet primary endpoints but showed consistent glycemic …
Biogen Inc. announced that the FDA has granted Breakthrough Therapy Designation to its investigational antisense oligonucleotide, salanersen, for treating spinal muscular atrophy (SMA). Supported by positive Phase 1b data showing motor function improvements and slowing neurodegeneration in children with SMA, salanersen offers potential high efficac…
Microchip Technology's Armenian office has received a U.S. Department of Commerce export license authorizing them to develop advanced FPGA technologies within Armenia. This approval strengthens Armenia's role in the global semiconductor supply chain and supports Microchip’s commitment to innovation through expanded global engineering collaboration.
Global-e Online Ltd., a leading global direct-to-consumer e-commerce platform, announced that its Board of Directors has authorized a new share repurchase program of up to $500 million. This follows completion of about 80% of their previous $200 million repurchase plan. The program aims to return capital to shareholders while supporting strategic i…
The Catalyst/Millburn Hedge Strategy Fund (MBXIX) has exceeded $10 billion in assets under management, signaling increasing investor demand for alternative investment strategies that offer diversification and resilience through both bull and bear markets. The fund employs a systematic long/short managed futures approach combined with strategic equi…
Plug Power Inc. announced its annual shareholder meeting webcast will take place on June 11, 2026, featuring a presentation by CEO Jose Luis Crespo on the company’s corporate overview and operations in the hydrogen economy. The webcast is accessible to shareholders and the public, highlighting Plug Power's progress in hydrogen solutions, electrolyz…
Option Care Health, the largest independent provider of home and alternate site infusion services in the US, announced the appointment of Robert Okunski as Vice President of Investor Relations. Okunski brings over 20 years of expertise in investor relations across healthcare and technology sectors and will lead the company's strategy to improve com…
AEON Biopharma announced presentation of new analytical and functional data at the 68th Annual Scientific Meeting of the American Headache Society demonstrating structural and functional comparability of its biosimilar candidate ABP-450 to BOTOX®. The data reinforce biosimilarity using multiple analytical methods, supporting AEON's pursuit of full-…
Axsome Therapeutics presented new clinical data on SYMBRAVO®, its investigational migraine treatment, at the American Headache Society 68th Annual Scientific Meeting. The data highlights SYMBRAVO's efficacy and safety in acute migraine treatment from multiple studies, supporting its potential market impact in CNS disorder therapeutics. Axsome conti…
U.S. Energy Corp. officially changes its name and ticker symbol to Big Sky Industrial Inc. to reflect its strategic focus on helium production, carbon management through its Big Sky Carbon Hub project in Montana, and low-decline oil operations. The company has reached final investment decision on processing facilities, secured contracted cash flows…
BeyondSpring Inc., a clinical-stage biopharmaceutical company, announced a strategic leadership transition effective July 1, 2026, to focus on executing its confirmatory DUBLIN-4 Phase 3 trial for Plinabulin in non-squamous EGFR wild-type NSCLC patients. The company appoints Min Qiu as CEO with a mandate to complete DUBLIN-4, extend Plinabulin's sc…
Orion Energy Systems, Inc. (NASDAQ: OESX), a provider of energy-efficient LED lighting, EV charging stations, and maintenance services, announced its fiscal 2026 results featuring $86.3 million in revenue, an 8% increase year-over-year, and positive adjusted EBITDA of $2.2 million after six consecutive quarters of profitability. The company reporte…
Syndax Pharmaceuticals has entered into a private placement agreement to issue $250 million of 2.25% Convertible Senior Notes due in 2031. The proceeds will be used for general corporate purposes, including R&D, commercialization, and business development. The notes carry an initial conversion price representing a 35% premium over recent trading pr…
Ovid Therapeutics Inc., a biopharmaceutical company specializing in treatments for brain disorders with significant unmet needs, announced its management will participate in two upcoming investor conferences. The presentations will provide updates on their pipeline, including therapies targeting treatment-resistant seizures and neuropsychiatric dis…
Fractyl Health announced positive one-year results from its open-label REVEAL-1 study showing that participants maintained approximately 78% of their GLP-1-induced weight loss after discontinuing GLP-1 therapy following a single Revita procedure. The procedure demonstrated excellent safety, sustained glycemic control, and potential as a durable, mi…
Electra Battery Materials has awarded a $12.4 million contract to Kilmarnock Enterprises for structural, mechanical, and piping work at its cobalt sulfate refinery north of Toronto, supporting its strategy to develop a domestic EV battery materials supply chain. This contract is part of approximately $46 million in awarded construction packages, wi…
Gogo Inc. announced that its SD Government division secured a multi-year $7.5 million contract with NOAA to provide L-Band satellite communications, ground infrastructure, cybersecurity solutions, and advanced cockpit software for NOAA's Hurricane Hunter aircraft, supporting vital storm research and real-time data transmission ahead of hurricane se…
Ocular Therapeutix, a biopharmaceutical company specializing in retinal diseases, announced its scheduled presentations at Clinical Trials at the Summit 2026. The company will share updates on its Phase 3 clinical trials of AXPAXLI (OTX-TKI), an investigational treatment targeting wet age-related macular degeneration and diabetic retinal diseases. …
Tilray Brands' subsidiary, Breckenridge Distillery, has introduced Breckenridge Rye Whiskey, a bold and richly flavored 100 proof rye whiskey crafted at 9,600 feet in Colorado. This new product builds on the distillery's reputation for quality and innovation and will be available in Colorado now and nationally in summer 2026.
Regeneron Pharmaceuticals announced upcoming presentations at the 2026 ADA and ENDO meetings highlighting new clinical and preclinical data from their metabolic disease, ophthalmology, and rare disease drug pipelines. Key focus includes the Phase 2 COURAGE trial on muscle and metabolic health, early data on Graves' and thyroid eye disease, and pivo…
LeonaBio, a clinical-stage biopharmaceutical company, presented its ALS drug candidate brelgometon (ATH-1105) at the 5th Annual ALS Drug Development Summit. The presentation highlighted the oral, brain-penetrant drug's mechanism and supporting Phase 1 and preclinical data. LeonaBio plans to initiate a randomized, placebo-controlled Phase 2 proof-of…
